Levetiracetam for managing neurologic and psychiatric disorders
- PMID: 19265183
- DOI: 10.2146/ajhp070607
Levetiracetam for managing neurologic and psychiatric disorders
Abstract
Purpose: The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed.
Summary: Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in the treatment of multiple seizure disorders, including generalized tonic-clonic; absence; myoclonic, especially juvenile myoclonic; Lennox-Gastaut syndrome; and refractory epilepsy in children and adults. Data are emerging on possible uses of levetiracetam outside the realm of epilepsy because of its unique mechanisms of action. There is preliminary evidence about the efficacy of levetiracetam in the treatment of different psychiatric disorders, including anxiety, panic, stress, mood and bipolar, autism, and Tourette's syndrome. The most serious adverse effects associated with levetiracetam use are behavioral in nature and might be more common in patients with a history of psychiatric and neurobehavioral problems.
Conclusion: Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders. The benefit-risk ratio in an individual patient with a specific condition should be used to determine its optimal use. Levetiracetam's use in nonepileptic conditions is not recommended until more data become available from larger trials.
Similar articles
-
Potential of levetiracetam in mood disorders: a preliminary review.CNS Drugs. 2006;20(12):969-79. doi: 10.2165/00023210-200620120-00002. CNS Drugs. 2006. PMID: 17140277 Review.
-
Levetiracetam in refractory pediatric epilepsy.J Child Neurol. 2002 Jun;17(6):413-5. doi: 10.1177/088307380201700603. J Child Neurol. 2002. PMID: 12174960 Clinical Trial.
-
Spotlight on levetiracetam in epilepsy.CNS Drugs. 2011 Oct 1;25(10):901-5. doi: 10.2165/11208340-000000000-00000. CNS Drugs. 2011. PMID: 21936590 Review.
-
Levetiracetam in pediatrics.J Child Neurol. 2005 Feb;20(2):87-93. doi: 10.1177/08830738050200020101. J Child Neurol. 2005. PMID: 15794171 Review.
-
[Antiepileptic drugs in North America].Brain Nerve. 2010 May;62(5):519-26. Brain Nerve. 2010. PMID: 20450099 Review. Japanese.
Cited by
-
Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior.Epilepsy Behav Case Rep. 2013 Aug 13;1:110-2. doi: 10.1016/j.ebcr.2013.07.002. eCollection 2013. Epilepsy Behav Case Rep. 2013. PMID: 25667841 Free PMC article.
-
Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy.Pharmaceutics. 2020 Oct 1;12(10):943. doi: 10.3390/pharmaceutics12100943. Pharmaceutics. 2020. PMID: 33019727 Free PMC article.
-
Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.Front Neurol. 2014 Jan 31;5:11. doi: 10.3389/fneur.2014.00011. eCollection 2014. Front Neurol. 2014. PMID: 24550884 Free PMC article. Review.
-
Levetiracetam Mechanisms of Action: From Molecules to Systems.Pharmaceuticals (Basel). 2022 Apr 13;15(4):475. doi: 10.3390/ph15040475. Pharmaceuticals (Basel). 2022. PMID: 35455472 Free PMC article. Review.
-
The relationship between psychiatric symptoms and the use of levetiracetam in people with epilepsy.Int J Psychiatry Med. 2024 May;59(3):360-372. doi: 10.1177/00912174231206056. Epub 2023 Oct 13. Int J Psychiatry Med. 2024. PMID: 37837222 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
